30 May 2019: The global Glycomics/Glycobiology Market is expected to grow at a CAGR of 14.4% in the forthcoming period. Glycomics is a wide and emerging scientific field emphasizing on defining functional aspects of glycans in biological systems. The higher the complexity of glycome, which is defined as the range of glycans particularly in a cell or organism leads to multiple challenges that could be subjectively decoded.
The challenges are resolved with progress in mass spectrometry along with expansion of genetic and cell biology studies. On the contrary, determining a specific glycan and glycan-binding proteins by incorporating new technology of glycan microarrays guide the glycan function.
Glycomics/glycobiology industry is driven by factors such as growing investments for R&D with a strong emphasis of pharmaceutical and biotechnology companies on innovative product development. Rise in development of new vaccines for genetic diseases comprising diabetes and influenza will add to the market growth in the forecast period. Rise in government funding for R&D activities and novel approach for drug production process are the other factors driving the market.
Product segmentation for glycomics market includes enzymes, reagents, kits and instruments. Enzymes are further quad furcated into glycosyltransferases, neuraminidases, sialyl transferases and glycosidases. Enzyme segment accounts for a high market share due to wide applications for various drug recovery procedures. Application segment for glycomics/glycobiology industry includes drug discovery &development diagnostics.
https://www.millioninsights.com/industry-reports/glycomics-glycobiology-market
Regional segmentation for glycomics/glycobiology market includes North America, Latin America, Europe, Asia-Pacific, Middle East and Africa. North America dominates the market due to high revenue share and presence of large pharmaceutical & biotechnology firms. Presence of developed healthcare infrastructure and availability of advanced products in these regions is likely to promote the market growth.
Asia-Pacific’s glycobiology industry is estimated to grow at a higher CAGR in the forecast period due to booming healthcare infrastructure in emerging economies. Availability of large pool of patients and low cost of clinical trials and accessibility of skilled personnel have propelled the market growth in Asia-Pacific’s market. The key players in the glycomics/glycobiology market include Thermo Fisher Scientific Inc, Agilent Technologies, Bruker, Merck KGaA, Shimazdu Corp, New England Biolabs, Waters Corporation, and Takara Bio Inc.
No comments:
Post a Comment